Table 3. Risk of Child’s Abnormal Developmental Screen at Ages 12, 18, and 24 Months by Trimester of Infection, Breakthrough Infection, and Febrile Infectiona.
| Primary exposure | Risk ratio (95% CI) | |
|---|---|---|
| Unadjusted | Adjusted | |
| Child developmental delay assessment at age 12 months | ||
| Trimester of prenatal infectionb | ||
| First | 1.15 (0.88-1.50) | 1.12 (0.83-1.50) |
| Second | 1.21 (0.81-1.82) | 1.12 (0.72-1.76) |
| Third | 0.92 (0.58-1.44) | 0.92 (0.56-1.49) |
| Breakthrough infectionc | 0.88 (0.46-1.68) | 0.88 (0.43-1.79) |
| Febrile infectiond | 1.24 (0.77-1.98) | 1.08 (0.60-1.92) |
| Child developmental delay assessment at age 18 months | ||
| Trimester of prenatal infectionb | ||
| First | 1.31 (0.93-1.85) | 1.43 (0.99-2.08) |
| Second | 0.97 (0.49-1.93) | 1.04 (0.53-2.03) |
| Third | 0.81 (0.41-1.60) | 0.73 (0.35-1.52) |
| Breakthrough infectionc | 0.26 (0.04-1.66) | 0.29 (0.04-1.97) |
| Febrile infectiond | 0.34 (0.09-1.31) | 0.30 (0.09-1.02) |
| Child developmental delay assessment at age 24 months | ||
| Trimester of prenatal infectionb | ||
| First | 1.21 (0.78-1.87) | 1.03 (0.61-1.75) |
| Second | 1.48 (0.80-2.74) | 1.44 (0.74-2.78) |
| Third | 0.68 (0.30-1.56) | 0.66 (0.28-1.55) |
| Breakthrough infectionc | 0.29 (0.04-1.86) | 0.31 (0.05-1.82) |
| Febrile infectiond | 0.40 (0.11-1.48) | 0.34 (0.07-1.65) |
a
Stratified estimates were generated using marginal probabilities from the fully adjusted model (model 3) plus an interaction between exposure and month of delay.
b
No prenatal infection is the reference.
c
Maternal SARS-CoV-2 infection following COVID-19 vaccination. Infection not preceded by vaccination is the reference.
d
Nonfebrile infection (≤38 °C) is the reference.